Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4 ...

Drug related deaths have soared to a record high with deaths involving cocaine up by almost a third, worrying new figures have revealed. Some 5,448 deaths were linked to drug poisoning in England ...

(Office of the Special Narcotics Prosecutor in New York via AP) A recreational drug called “pink cocaine” is getting attention and causing confusion since it doesn’t typically contain cocaine. The ...

Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4 ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

Kisqali also demonstrated a benefit in invasive disease-free survival versus endocrine therapy alone, with three-year invasive disease-free survival rates of 90.4 percent and 87.1 percent, ...